Dihydroxyphosphinecarboxylic acid oxide en es it fr

Dihydroxyphosphinecarboxylic acid oxide Brand names, Dihydroxyphosphinecarboxylic acid oxide Analogs

Dihydroxyphosphinecarboxylic acid oxide Brand Names Mixture

  • No information avaliable

Dihydroxyphosphinecarboxylic acid oxide Chemical_Formula

CH3O5P

Dihydroxyphosphinecarboxylic acid oxide RX_link

http://www.rxlist.com/cgi/generic2/foscarnet.htm

Dihydroxyphosphinecarboxylic acid oxide fda sheet

Dihydroxyphosphinecarboxylic acid oxide msds (material safety sheet)

Dihydroxyphosphinecarboxylic_acid_oxide MSDS

Dihydroxyphosphinecarboxylic acid oxide Synthesis Reference

Noren, Jan O.; et al., J.Med.Chem. 26(2) 264-270(1983)

Dihydroxyphosphinecarboxylic acid oxide Molecular Weight

126.005 g/mol

Dihydroxyphosphinecarboxylic acid oxide Melting Point

88.06 oC

Dihydroxyphosphinecarboxylic acid oxide H2O Solubility

Complete

Dihydroxyphosphinecarboxylic acid oxide State

Solid

Dihydroxyphosphinecarboxylic acid oxide LogP

No information avaliable

Dihydroxyphosphinecarboxylic acid oxide Dosage Forms

Injection

Dihydroxyphosphinecarboxylic acid oxide Indication

For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.

Dihydroxyphosphinecarboxylic acid oxide Pharmacology

Foscarnet is an organic analogue of inorganic pyrophosphate that inhibits replication of herpes viruses in vitro including cytomegalovirus (CMV) and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Foscarnet does not require activation (phosphorylation) by thymidine kinase or other kinases and therefore is active in vitro against HSV TK deficient mutants and CMV UL97 mutants. Thus, HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to foscarnet. However, acyclovir or ganciclovir resistant mutants with alterations in the viral DNA polymerase may be resistant to foscarnet and may not respond to therapy with foscarnet. The combination of foscarnet and ganciclovir has been shown to have enhanced activity in vitro.

Dihydroxyphosphinecarboxylic acid oxide Absorption

Poorly absorbed after oral administration (bioavailability from 12 to 22%).

Dihydroxyphosphinecarboxylic acid oxide side effects and Toxicity

Oral, rat LD50: >2,000 mg/kg. Signs of overdose include renal impairment.

Dihydroxyphosphinecarboxylic acid oxide Patient Information

Dihydroxyphosphinecarboxylic acid oxide Organisms Affected

Human herpes viruses